Chris Degnan is CFO at UroGen Pharma Ltd. (URGN). They have made 4 open-market trades across 3 companies since 2018, most recently 2026-10-08.
CIK 0001741968
2 open-market purchases totalling $65K since 2018, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| URGN | 4,561 | $131K |
| VRCA | 3,000 | $10K |
| GRTX | 10,000 | $1K |
| Total | $143K |
Shares reported on the most recent Form 4, priced at the 2026-10-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.